16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

NCT02008916 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Spondylitis, Ankylosing

Interventions

DRUG: Secukinumab
DRUG: Placebo secukinumab

Sponsor

Novartis Pharmaceuticals